Total Payments
$1.6M
2024 Payments
$188,017
Companies
28
Transactions
927
Medicare Patients
1,689
Medicare Billing
$363,224
Payment Breakdown by Category
Other$671,170 (42.3%)
Consulting$422,968 (26.6%)
Research$355,897 (22.4%)
Travel$121,008 (7.6%)
Food & Beverage$16,206 (1.0%)
Education$825.48 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $631,214 | 207 | 39.7% |
| Consulting Fee | $422,968 | 166 | 26.6% |
| Unspecified | $355,897 | 80 | 22.4% |
| Travel and Lodging | $121,008 | 206 | 7.6% |
| Honoraria | $36,954 | 13 | 2.3% |
| Food and Beverage | $16,206 | 249 | 1.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,002 | 4 | 0.2% |
| Education | $825.48 | 2 | 0.1% |
Payments by Type
General
$1.2M
847 transactions
Research
$355,897
80 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ichnos Sciences Inc. | $258,234 | 19 | $0 (2023) |
| Celgene Corporation | $199,815 | 157 | $0 (2024) |
| GENZYME CORPORATION | $176,303 | 89 | $0 (2024) |
| Amgen Inc. | $145,261 | 122 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $115,014 | 55 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $104,005 | 76 | $0 (2024) |
| Janssen Biotech, Inc. | $93,537 | 100 | $0 (2024) |
| Glenmark Pharmaceuticals Inc. | $73,397 | 5 | $0 (2018) |
| Karyopharm Therapeutics Inc. | $66,975 | 29 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $52,017 | 43 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $188,017 | 95 | GENZYME CORPORATION ($70,617) |
| 2023 | $313,214 | 131 | Ichnos Sciences Inc. ($150,423) |
| 2022 | $176,389 | 102 | GENZYME CORPORATION ($46,680) |
| 2021 | $201,916 | 102 | Karyopharm Therapeutics Inc. ($50,385) |
| 2020 | $162,741 | 67 | Ichnos Sciences Inc. ($64,170) |
| 2019 | $94,497 | 78 | Celgene Corporation ($70,644) |
| 2018 | $235,591 | 143 | Glenmark Pharmaceuticals Inc. ($73,397) |
| 2017 | $215,709 | 209 | Amgen Inc. ($82,029) |
All Payment Transactions
927 individual payment records from CMS Open Payments — Page 2 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/26/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $130.44 | General |
| 09/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $740.00 | General |
| 09/11/2024 | Stemline Therapeutics Inc. | — | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| 08/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,522.50 | General |
| 08/11/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $75.86 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Stemline Therapeutics Inc. | — | Consulting Fee | Cash or cash equivalent | $4,680.00 | General |
| 08/01/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: ONCOLOGY | ||||||
| 07/29/2024 | Stemline Therapeutics Inc. | — | Consulting Fee | Cash or cash equivalent | $7,997.00 | General |
| 07/26/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Oncology | ||||||
| 07/26/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,965.00 | General |
| 07/09/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $141.41 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 07/06/2024 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $20,937.00 | General |
| Category: Oncology | ||||||
| 07/06/2024 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Travel and Lodging | Cash or cash equivalent | $192.55 | General |
| Category: Oncology | ||||||
| 07/05/2024 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,490.00 | General |
| Category: Oncology | ||||||
| 07/05/2024 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,994.00 | General |
| Category: Oncology | ||||||
| 07/05/2024 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $1,662.00 | General |
| Category: Oncology | ||||||
| 07/04/2024 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,496.00 | General |
| Category: Oncology | ||||||
| 07/04/2024 | SANOFI-AVENTIS U.S. LLC | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $831.00 | General |
| Category: Oncology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $394.26 | Research |
| Study: Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients | ||||||
| 06/28/2024 | Janssen Global Services, LLC | DARZALEX (Biological), CARVYKTI, TALVEY | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| Category: Oncology | ||||||
| 06/28/2024 | Celgene Corporation | ABECMA (Biological) | Food and Beverage | Cash or cash equivalent | $26.10 | General |
| Category: Oncology | ||||||
| 06/14/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $310.40 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 06/14/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), CARVYKTI, TECVAYLI | Food and Beverage | In-kind items and services | $119.19 | General |
| Category: Oncology | ||||||
| 06/13/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $14,955.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1342-101 | Ichnos Sciences Inc. | $258,234 | 19 |
| PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | Regeneron Pharmaceuticals, Inc. | $9,740 | 36 |
| ISB 1342-101 | IGI Inc | $3,743 | 1 |
| Phase I II Cevostamab in Prior BCMA Exposed r r Multiple Myeloma patients | F. Hoffmann-La Roche AG | $1,539 | 3 |
| PHASE 1/2 FIH STUDY OF REGN5459 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | Regeneron Pharmaceuticals, Inc. | $1,532 | 2 |
| A PHASE 1/2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PK/PD STUDY OF SHP655 (RADAMTS13) IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS | Takeda Pharmaceuticals U.S.A., Inc. | $1,480 | 1 |
| REGN5458 CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,401 | 4 |
| Multiple myeloma - SCT subgroups | GENZYME CORPORATION | $1,250 | 1 |
| Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38 Hematological Malignancies | GENZYME CORPORATION | $1,051 | 3 |
| Ph I of FcRH5 CD3 in multiple myeloma | F. Hoffmann-La Roche AG | $1,050 | 2 |
| Comparison of Efficacy Outcomes for Carfilzomib Plus Dexamethasone and Daratumumab (KdD) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) and D-Pd in Relapsed or Refractory Multiple Myeloma | Amgen Inc. | $867.10 | 1 |
| Comparison of Efficacy Outcomes for Carfilzomib Plus Dexamethasone and Daratumumab (KdD) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) and D-Pd in Relapsed or Refractory Multiple Myeloma | Amgen Inc. | $481.80 | 1 |
| Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | GENZYME CORPORATION | $129.92 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 513 | 909 | $383,320 | $90,233 |
| 2022 | 6 | 433 | 935 | $417,810 | $100,757 |
| 2021 | 8 | 423 | 976 | $442,545 | $110,321 |
| 2020 | 8 | 320 | 649 | $293,093 | $61,913 |
Total Patients
1,689
Total Services
3,469
Medicare Billing
$363,224
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 133 | 257 | $104,750 | $22,071 | 21.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 89 | 170 | $92,440 | $21,157 | 22.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 49 | 88 | $38,720 | $10,822 | 27.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 89 | $36,490 | $9,657 | 26.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 57 | 87 | $26,970 | $7,550 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 64 | 87 | $23,340 | $5,058 | 21.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 61 | $18,300 | $4,402 | 24.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $16,750 | $4,152 | 24.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $11,360 | $2,310 | 20.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 14 | $11,200 | $2,213 | 19.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 15 | $3,000 | $842.94 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 115 | 278 | $153,380 | $35,232 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 60 | 127 | $55,880 | $16,577 | 29.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 149 | $61,090 | $15,286 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 91 | 153 | $61,590 | $12,500 | 20.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 33 | 103 | $30,900 | $7,213 | 23.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 39 | 61 | $18,910 | $5,170 | 27.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $19,430 | $4,836 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $11,840 | $2,761 | 23.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 19 | $4,790 | $1,183 | 24.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 99 | 310 | $170,000 | $39,868 | 23.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 67 | 173 | $76,120 | $23,425 | 30.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 50 | 172 | $70,520 | $16,390 | 23.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 50 | 121 | $36,300 | $8,082 | 22.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 48 | 74 | $29,210 | $6,662 | 22.8% |
About Dr. Joshua Richter, M.D
Dr. Joshua Richter, M.D is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/29/2008. The National Provider Identifier (NPI) number assigned to this provider is 1982879128.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joshua Richter, M.D has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $188,017 received in 2024. These payments were reported across 927 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($631,214).
As a Medicare-enrolled provider, Richter has provided services to 1,689 Medicare beneficiaries, totaling 3,469 services with total Medicare billing of $363,224. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 04/29/2008
- Last Updated 02/26/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1982879128
Products in Payments
- Revlimid (Drug) $122,284
- DARZALEX (Biological) $122,262
- SARCLISA (Biological) $113,589
- NINLARO (Drug) $108,910
- Kyprolis (Biological) $107,095
- XPOVIO (Drug) $66,975
- ISB 1342-101 (Drug) $64,170
- EMPLICITI (Biological) $45,272
- clonoSEQ (Device) $29,422
- CUVITRU (Biological) $27,994
- XGEVA (Biological) $26,582
- FARYDAK (Drug) $25,172
- Pomalyst (Drug) $19,346
- Farydak (Drug) $18,165
- TECVAYLI (Biological) $18,163
- XARELTO (Drug) $10,433
- DARZALEX (Drug) $7,763
- Blincyto (Biological) $7,525
- IMBRUVICA (Drug) $4,832
- CD38 (Drug) $4,578
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555
Kevin Kalinsky, M.d, M.D
Medical Oncology — Payments: $471,305
Medical Oncology $471,305